Efficacy Ultrasound-guided Genicular Nerve Radiofrequency Treatment
Launched by YUNUS BURAK BAYIR · Jun 27, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for chronic knee pain caused by gonarthrosis, which is a type of arthritis affecting the knee. The treatment involves using radiofrequency (RF) energy, guided by ultrasound, to block pain signals from specific nerves in the knee. By targeting these nerves, the goal is to reduce pain and improve knee function for patients who have been experiencing significant discomfort for at least three months.
To participate in the study, individuals must be over 18 years old, have been diagnosed with advanced gonarthrosis (stages 3-4) and have persistent anterior knee pain that hasn't improved with other treatments. Some people may not be eligible, including those who are pregnant, have had recent knee surgery, or have certain medical conditions. Participants can expect to receive the RF treatment, and researchers will monitor how well it helps with their knee pain and overall movement. This trial aims to provide valuable information about this treatment's effectiveness for those suffering from knee pain related to gonarthrosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Being a male/female \>18
- • 2. K-L stage 3-4 gonarthrosis patients with anterior knee pain and positive patellofemoral pain tests after physical examination and imaging evaluation
- • 3. Those whose symptoms persist for \>3 months
- • 4. Participating in the study voluntarily
- Exclusion Criteria:
- • 1. Pregnancy
- • 2. History of previous knee surgery
- • 3. Having received physical therapy in the knee area in the last 3 months
- • 4. Having previously undergone RF treatment or having had any therapeutic injection such as steroids or hyaluronic acid within 3 months.
- • 5. Those with pain referred to the waist or hip
- • 6. Patients with neuropathic pain
- • 7. History of tumor, infectious, psychiatric disease, bleeding diathesis
- • 8. Having a history of knee trauma in the last 6 months
- • 9. Those with systemic diseases such as hepatitis and coagulopathy
- • 10. Patients with BMI \>40
- • 11. Leg length difference
About Yunus Burak Bayır
Yunus Burak Bayır is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing effective therapeutic solutions, the organization collaborates with healthcare professionals and research institutions to design and implement rigorous clinical trials. Leveraging a strong foundation in scientific expertise and regulatory compliance, Yunus Burak Bayır aims to enhance patient care by bringing new treatments to market while prioritizing safety and ethical standards in all research activities. Through strategic partnerships and a commitment to excellence, the sponsor plays a pivotal role in the progression of clinical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Ayşegül Yaman, specialist
Study Chair
Ankara Etlik City Hospital
Başak Mansız Kaplan, assoc. prof.
Study Chair
Ankara Etlik City Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported